Date: 2012-09-20
Type of information: Nomination
Compound:
Company: Bind Biosciences (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 20, 2012, Bind Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins™, announced the appointment of Daniel S. Lynch as Chairman of the company’s board of directors. Dan Lynch brings more than 25 years of experience serving in management and board positions in the biotechnology and pharmaceutical industries. Dan spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CEO, he led ImClone through a significant turnaround, including securing FDA approval of Erbitux® (cetuximab). As CFO, Dan led negotiations to form the major partnership between ImClone and BMS. Earlier in his career, he served in various financial positions at BMS over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December, 2010, when it was acquired by McKesson. More recently Dan was Executive Chairman of the board for Avila Therapeutics and Stromedix. In addition to BIND Biosciences, Dan is currently a member of the board of directors for bluebird bio, Edimer Pharmaceuticals, and Ember Therapeutics. Dan received his BA in Mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.
Financial terms:
Latest news:
